| Price | 13,284.00p on 16-06-2026 at 18:11:11 |
|---|---|
| Change | 84.00p 0.64% |
| Buy | 13,270.00p |
| Sell | 13,266.00p |
| Last Trade: | Unknown 0.00 at 13,333.24025p |
| Day's Volume: | 4,260,476 |
| Last Close: | 13,284.00p |
| Open: | 13,248.00p |
| ISIN: | GB0009895292 |
| Day's Range | 13,172.00p - 13,320.00p |
| 52wk Range: | 10,104.00p - 15,730.00p |
| Market Capitalisation: | £206.02b |
| VWAP: | 13,259.72133p |
| Shares in Issue: | 1.55b |
Astrazeneca (AZN) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 0 | 13,333.24025p | SI Trade Currency Conversion |
19:11:11 - 16-Jun-26 |
| Unknown* | 4 | 13,352.64057p | Currency Conversion Negotiated Trade OTC Trade |
18:59:27 - 16-Jun-26 |
| Unknown* | 3 | 13,348.90974p | SI Trade Currency Conversion |
18:46:52 - 16-Jun-26 |
| Unknown* | 0 | 13,345.92508p | SI Trade Currency Conversion |
18:42:44 - 16-Jun-26 |
| Unknown* | 0 | 13,336.22492p | SI Trade Currency Conversion |
18:37:24 - 16-Jun-26 |
| Unknown* | 3 | 13,338.8365p | Currency Conversion Negotiated Trade OTC Trade |
18:35:02 - 16-Jun-26 |
| Unknown* | 0 | 13,341.44808p | SI Trade Currency Conversion |
18:33:36 - 16-Jun-26 |
| Unknown* | 0 | 13,335.47875p | SI Trade Currency Conversion |
18:28:35 - 16-Jun-26 |
| Unknown* | 1 | 13,333.97896p | Currency Conversion Negotiated Trade OTC Trade |
18:00:28 - 16-Jun-26 |
| Unknown* | 0 | 13,350.40207p | SI Trade Currency Conversion |
17:45:07 - 16-Jun-26 |
Astrazeneca (AZN) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 15th Jun 2026 7:00 am | RNS | Truqap approved in US for prostate cancer |
| 1st Jun 2026 3:05 pm | RNS | Admission of Further Securities to Trading |
| 1st Jun 2026 3:00 pm | RNS | Total Voting Rights |
| 29th May 2026 7:00 am | RNS | Imfinzi approved in US for early bladder cancer |
| 27th May 2026 7:00 am | RNS | US FDA decision date on camizestrant extended |
| 26th May 2026 7:00 am | RNS | Enhertu recommended in EU for HER2+ solid tumours |
| 26th May 2026 7:00 am | RNS | Camizestrant recommended for breast cancer in EU |
| 26th May 2026 7:00 am | RNS | Datroway approved in US for 1L triple-negative BC |
| 18th May 2026 3:00 pm | RNS | Director/PDMR Shareholding |
| 18th May 2026 7:05 am | RNS | Enhertu approved in two HER2+ early BC settings |
